Huperzine A

石杉碱甲

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameHuperzine A
Drug Alias NameHupAHupA oralHuperzine A oralQian-ceng-ta哈伯因 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAcetylcholinesterase inhibitors
TargetsAcetylcholinesterase
Therapy Area/IndicationsSchizophreniaSeizuresMemory Disorders +[7] 
Global Approved IndicationsAlzheimer Disease
Approved Indications in ChinaAlzheimer Disease
Original Approved Country/TerritoryMainland China
Original Approved Date1994/01/01
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMayo ClinicChinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesSupernus Pharmaceuticals IncHenan Taloph Pharmaceutical Stock Co LtdUniversal Pharmaceutical Group Co Ltd +[4] 
Inactive CompaniesThe Spaulding Rehabilitation Hospital CorpNational Institute On Aging (NIA)Shandong Luye Natural Medicine Research And Development Co Ltd +[5] 
Active IndicationsSeizuresMemory DisordersLearning Disabilities +[5] 
Inactive IndicationsSchizophreniaBrain Injuries, Traumatic

Other Information

ATC CodeN06
Related LinksWikipediaDrugBank